We're pleased to partner with Ferrer to co-develop VRG50635, our lead drug candidate for the treatment of sporadic and familial forms of #ALS. Hear our President and Chief Business Officer, Jane Rhodes, share how our #innovation and Ferrer's experience create a complementary partnership as we progress a potential treatment for this devastating disease. #biotechnology #drugdevelopment
We are delighted to announce an important news for people living with amyotrophic lateral sclerosis (ALS), their families, and their caregivers, thanks to our a strategic collaboration with Verge Genomics to co-develop one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. According to Mario Rovirosa, our CEO, "in line with our purpose to use business to fight for social justice, we are reinforcing our commitment to bring transformative therapeutic solutions for people living with severe and debilitating diseases”. We are Ferrer. Ferrer for good 💙💚 More info: https://lnkd.in/diWtUBMx
Congratulations Jane Rhodes
SVP Research at Gain Therapeutics
4moCongratulations Jane Rhodes